Advanced search
Publication Cover
Acta Oncologica Volume 41, 2002 - Issue 7-8
Journal homepage
275
Views
29
CrossRef citations to date
0
Altmetric
Research Article

New Techniques and Agents in the Adjuvant Therapy of Pancreatic Cancer

Michael G. T. Raraty From the Department of Surgery, University of Liverpool, Royal Liverpool University Hospital, Liverpool, UK
,
Conor J. Magee From the Department of Surgery, University of Liverpool, Royal Liverpool University Hospital, Liverpool, UK
,
Paula Ghaneh From the Department of Surgery, University of Liverpool, Royal Liverpool University Hospital, Liverpool, UK
&
John P. Neoptolemos From the Department of Surgery, University of Liverpool, Royal Liverpool University Hospital, Liverpool, UK
Pages 582-595 | Published online: 08 Jul 2009

  • Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37: S4-S66.
  • Carter DC. Etiology and epidemiology of pancreatic and periampullary cancer. In: Trede M, Carter DC, eds. Surgery of the pancreas, 2nd ed. New York: Churchill Livingstone, 1997: 427-42.
  • Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; Sl: 15-36.
  • Coleman MP, Babb P, Damiecki P. Cancer survival trends in England and Wales, 1971-1995: deprivation and NHS region. London: Her Majesty's Stationery Office, 1999.
  • Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13560 pa-tients with pancreatic cancer, and incidence of the disease, in the West Midlands--an epidemiologic-study. Br J Surg 1995; 82: 111-5.
  • Allema JH, Reinders ME, van Gulik, et al. Prognostic factors for survival after pancreaticoduodenectomy for pa-tients with carcinoma of the pancreatic head region. Cancer 1995; 75: 2069-76.
  • Mosca F, Giulianotti PC, Balestracci T, et al. Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreatoduodenectomy. Surgery 1997; 122: 553-66.
  • Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocar-cinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-79.
  • Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Hoi-brook MA. Combined 5-fluorouracil and supervoltage radia-tion therapy of locally unresectable gastrointestinal cancer. Lancet 1969; 2 (7626): 865-7.
  • Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer results of a controlled, prospective, randomised, multicentre trial. Br Med J 1980; 281 (6255): 1589-91.
  • Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81: 882-5.
  • Glimelius B, Hoffman K, Sjöden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
  • Cullinan S, Moertel CG, Wieand HS, et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evalua-tions of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990; 65: 2207-12.
  • Splinter TA, Obertop H, Kok TC, Jeekel J. Adjuvant chemotherapy after resection of adenocarcinoma of the peri-ampullary region and the head of the pancreas. A non-ran-domized pilot study. J Cancer Res Clin Oncol 1989; 115: 200-2.
  • Bakkevold KE, Arnesjo B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resec-tion of carcinoma of the pancreas and papilla of Vater-re-suits of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993; 29A: 698-703.
  • Baumel H, Huguier M, Manderscheid JC, Fahre JM, Houry S, Fagot H. Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery. Br J Surg 1994; 81: 102-7.
  • Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancre-atic cancer: a randomised controlled trial. Lancet 2001; 358 (9293): 1576-85.
  • Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234: 758-68.
  • Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-7.
  • Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer a ran-domized trial. J Clin Oncol 1997; 15: 2403-13.
  • Ishikawa O, Ohigashi H, Sasaki Y, et al. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg 1994; 168: 361-4.
  • Ishikawa O, Ohigashi H, Imaoka S, et al. Regional chemotherapy to prevent hepatic metastasis after resection of pancreatic cancer. Hepato-Gastroenterology 1997; 44: 1541-6.
  • Gansauge F, Link KH, Rilinger N, Kunz R, Beger HG. Adjuvant regional chemotherapy in resected advanced pan-creas carcinoma. Chirurg 1996; 67: 362-5.
  • Link KH, Formentini A, Gansauge F, Papachristov E, Beger HG. Regional celiac artery infusion as adjuvant treat-ment after pancreatic cancer resection. Digestion 1997; 58: 529-32.
  • Beger HG, Gansauge F, Buchler MW, Link KH. Intraarte-rial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer significant reduction in occurrence of liver metastasis. World J Surg 1999; 23: 946-9.
  • Ozaki H, Kinoshita T, Kosuge T, et al. Long-term survival after multimodality treatment for resectable pancreatic can-cer. Int J Pancreatol 2000; 27: 217-24.
  • Willett CG, Lewandrowski K, Warshaw AL, Efird J, Comp-ton CC. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993; 217: 144-8.
  • Johnstone PA, Sindelar WF. Patterns of disease recurrence following definitive therapy of adenocarcinoma of the pan-creas using surgery and adjuvant radiotherapy: correlations of a clinical trial. Int J Radiat Oncol Biol Physics 1993; 27: 831-4.
  • Zerbi A, Fossati V, Parolini D, et al. Intraoperative radia-tion therapy adjuvant to resection in the treatment of pan-creatic cancer. Cancer 1994; 73: 2930-5.
  • Di Carlo V, Zerbi A, Balzano G, Villa E. Intraoperative and postoperative radiotherapy in pancreatic cancer. Int J Pan-creatol 1997; 21: 53-8.
  • Dobelbower RR, Merrick HW, Khuder S, Battle JA, Herren LM, Pawlicki T. Adjuvant radiation therapy for pancreatic cancer: a 15-year experience. Int J Radiat Oncol Biol Physics 1997; 39: 31-7.
  • Farrell TJ, Barbot DJ, Rosato FE. Pancreatic resection combined with intraoperative radiation therapy for pancre-atic cancer. Ann Surg 1997; 226: 66-9.
  • Hishinuma S, Ogata Y, Matsui J, Ozawa I. Results of surgery and adjuvant radiotherapy for pancreatic cancer. J Hepato-Bil-Pancreat Surg 1998; 5: 143-50.
  • Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radio-therapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-82; discussion: 782-4.
  • Mehta VK, Fisher GA, Ford JM, et al. Adjuvant radiother-apy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Physics 2000; 48: 1483-7.
  • Lee JH, Whittington R, Williams NN, et al. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Physics 2000; 47: 945-9453.
  • Alfleri S, Morganti AG, Di Giorgio A, et al. Improved survival and local control after intraoperative radiation ther-apy and postoperative radiotherapy: a multivariate analysis of 46 patients undergoing surgery for pancreatic head can-cer. Arch Surg 2001; 136: 343-7.
  • Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized compari-son of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radia-tion + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48: 1705-10.
  • Kaiser MH, Ellenberg SS. Pancreatic cancer. Adjuvant com-bined radiation and chemotherapy following curative resec-tion. Arch Surg 1985; 120: 899-903.
  • Douglas HO, Jr. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987; 59: 2006-10.
  • Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocar-cinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996; 223: 273-9.
  • Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduo-denectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225: 621-33; discussion: 633-6.
  • Neoptolemos JP. Adjuvant radiotherapy and follow-on chemotherapy in patients with pancreatic cancer. Results of the UK Pancreatic Cancer Group Study (UKPACA-1). GI Cancer 1998; 2: 235-45.
  • Abrams RA, Grochow LB, Chakravarthy A, et al. Inten-sified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Physics 1999; 44: 1039-46.
  • Andre T, Balosso J, Louvet C, et al. Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibil-ity study. Int J Radiat Oncol Biol Physics 2000; 46: 903-11.
  • Paulino AC. Resected pancreatic cancer treated with adju-vant radiotherapy with or without 5-fluorouracil: treatment results and patterns of failure. Am J Clin Oncol 1999; 22: 489-94.
  • Nukui Y, Picozzi VJ, Traverse LW. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2000; 179: 367-71.
  • Neoptolemos JP, Baker P, Spooner D, Cunningham D, Johnson CD. Adjuvant radiotherapy and follow-on chemotherapy in patients with pancreatic cancer. Results of the UK pancreatic cancer study group (UKPACA-1). GI Cancer 1998; 2: 235-45.
  • Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000; 89: 314-27.
  • Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000; 7: 39-58.
  • Rocha Lima CM, Sherman CA, Brescia FJ, Brunson CY, Green MR. Irinotecan/gemcitabine combination chemother-apy in pancreatic cancer. Oncology (Huntingdon) 2001; 15 (3 Suppl 5): 46-51.
  • Stehlin JS, Giovanella BC, Natelson EA, et al. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol 1999; 14: 821-31.
  • Bramhall SR, Stamp GW, Dunn J, Lemoine NR, Neoptole-mos JP. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMPl) in pancreatic and ampullary disease. Br J Cancer 1996; 73: 972-8.
  • Bramhall SR, Neoptolemos JP, Stamp GW, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metallo-proteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997; 182: 347-55.
  • Evans JD, Stark A, Johnson CD, et al. A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer 2001; 85: 1865-70.
  • Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA, Marimastat Pancreatic Cancer Study G. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 3447-55.
  • Ito T, Kawata S, Tamura S, et al. Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a famesyl:protein transferase inhibitor. Jpn J Cancer Res 1996; 87: 113-6.
  • Kroep JR, Pinedo HM, van Groeningen CJ, Peters GJ. Experimental drugs and drug combinations in pancreatic cancer. Ann Oncol 1999; 10 (Suppl 4): 234-8.
  • Rougier P, Adenis A, Ducreux M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000; 36: 1016-25.
  • Sherman WH, Fine RL. Combination gemcitabine and doc-etaxel therapy in advanced adenocarcinoma of the pancreas. Oncology 2001; 60: 316-21.
  • Casein u S, Gasparini G, Catalane V, et al. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 1999; 10: 1377-9.
  • Stathopoulos GP, Mavroudis D, Tsavaris N, et al. Treat-ment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancre-atic Cancer. Ann Oncol 2001; 12: 101-3.
  • Morgan JE, Blankenship JW, Matthews HR. Polyamines and acetylpolyamines increase the stability and alter the conformation of nucleosome core particles. Biochemistry 1987; 26: 3643-9.
  • Jones L, Ghaneh P, Humphreys M, Neoptolemos JP. The matrix metalloproteinases and their inhibitors in the treat-ment of pancreatic cancer. Ann N Y Acad Sei 1999; 880: 288-307.
  • Hotz HG, Reber HA, Hotz B, et al. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. J Gastrointest Surg 2001; 5: 131-8.
  • Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr Opin Oncol 2000; 12: 564-73.
  • Herzig MC, Arnett B, MacDonald JR, Woynarowski JM. Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF). Biochem Pharmacol 1999; 58: 217-25.
  • Keiner MJ, McMorris TC, Estes LA, et al. Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft. Anticancer Drugs 2000; 11: 217-24.
  • Weitman S, Marty J, Jolivet J, Locas C, Von Hoff DD. The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine) has activity against pancreatic human tumor xenografts. Clin Cancer R 2000; 6: 1574-8.
  • Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
  • Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
  • Kawesha A, Ghaneh P, Andren-Sandberg A, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, pl6(INK4A), p21(WAF-l), cyclin Dl, erbB-2 and erbB-3 in resected pancreatic ductal adenocar-cinoma. Int J Cancer 2000; 89: 469-74.
  • Buchler P, Reber HA, Buchler MC, et al. Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). J Gastrointest Surg 2001; 5: 139-46.
  • Safran H, Ramanathan RK, Schwartz J, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overex-press HER-2/neu. San Francisco: ASCO 2001.
  • Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993; 13: 565-9.
  • Schmiegel W, Schmielau J, Henne-Bruns D, et al. Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the ther-apy of pancreatic cancer. Proc Natl Acad Sei USA 1997; 94: 12622-6.
  • Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr ReI Cancer 2001; 8: 3-9.
  • Jaffee EM, Abrams R, Cameron J, et al. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther 1998; 9: 1951-71.
  • Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allo-geneic granulocyte-macrophage colony-stimulating factor-se-creting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19: 145-56.
  • Gjertsen MK, Buanes T, Rosseland et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001; 92: 441-50.
  • Przepiorka D, Srivastava PK. Heat shock protein-peptide complexes as immunotherapy for human cancer. MoI Med Today 1998; 4: 478-84.
  • Lewis JJ, Janetzki S, Livingston PO, et al. Pilot trial of vaccination with autologous tumor-derived gp96 heat shock protein-peptide complex (HSPPC-96) in patients with resected pancreatic adenocarcinoma. San Fransisco: ASCO 1999.
  • Watson SA, Michael D, Justin TA, et al. Pre-clinical evalua-tion of the gastrimmune immunogen alone and in combina-tion with 5-fluorouracil/leucovorin in a rat colorectal cancer model. Int J Cancer 1998; 75: 873-7.
  • Kita K, Saito S, Morioka CY, Watanabe A. Growth inhibi-tion of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int J Can-cer 1999; 80: 553-8.
  • Magee CJ, Greenhalf W, Howes N, Ghaneh P, Neoptolemos JP. Molecular pathogenesis of pancreatic ductal adenocar-cinoma and clinical implications. Surg Oncol-Oxford 2001; 10: 1-23.
  • Bouvet M, Bold RJ, Lee J, et al. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apop-tosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol 1998; 5: 681-8.
  • Ghaneh P, Greenhalf W, Humphreys M, et al. Adenovirus-mediated transfer of p53 and pl6INK4a results in pancreatic cancer regression in vitro and in vivo. Gene Ther 2001; 8: 199-208.
  • Kasuya H, Nishiyama Y, Nomoto S, Hosono J, Takeda S, Nakao A. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic can-cer. J Surg Oncol 1999; 72: 136-41.
  • Carrio M, Romagosa A, Mercade E, et al. Enhanced pancre-atic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene. Gene Ther 1999; 6: 547-53.
  • Humphreys MJ, Ghaneh P, Greenhalf W, et al. Hepatic intra-arterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine sup-presses growth of colorectal liver metastases. Gene Ther 2001; 8: 1241-7.
  • McNeish IA, Green NK, Gilligan MG, et al. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther 1998; 5: 1061-9.
  • Green NK, Youngs DJ, Neoptolemos JP, et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-l-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 1997; 4: 229-38.
  • Lohr M, Hoffmeyer A, Kroger J, et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 2001; 357 (9268): 1591-2.
  • Kachnic LA, Shaw JE, Manning MA, Lauve AD, Neifeld JP. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pan-creas. Int J Cancer 2001; 96: 132-9.
  • Ishikawa O, Ohigashi H, Imaoka S, et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head? Arch Surg 1994; 129: 1075-80.
  • Coia L, Hoffman J, Scher R, et al. Preoperative chemoradi-ation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Physics 1994; 30: 161-7.
  • Staley CA, Lee JE, Cleary KR, et al. Preoperative chemora-diation, pancreaticoduodenectomy, and intraoperative radia-tion therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996; 171:118-24; discussion: 124-5.
  • Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15: 928-37.
  • Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB, 3rd. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, re-sectable adenocarcinoma of the pancreas: an Eastern Coop-erative Oncology Group Study. J Clin Oncol 1998; 16: 317-23.
  • White R, Lee C, Anscher M, et al. Preoperative chemoradia-tion for patients with locally advanced adenocarcinoma of the pancreas. Ann Surg Oncol 1999; 6: 38-45.
  • Wanebo HJ, Glicksman AS, Vezeridis MP, et al. Preopera-tive chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg 2000; 135: 81-7; discussion: 88.
  • Mehta VK, Fisher G, Ford JA, et al. Preoperative chemora-diation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg 2001; 5: 27-35.
  • Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8: 123-32.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.